News

Prosonix cashes in £17.1m
Enlarge image

BusinessBelgiumUK

Prosonix cashes in £17.1m

23.05.2012 - British respiratory medicines company Prosonix Ltd. has extended its Series B financing round to £17.1m.

Oxford – The lion’s share of the new capital comes from new investor Gimv, a leading European technology investor, who contributed £5.7m. The rest was contributed by the syndicate of investors that participated in the first closing of the round in June 2011. The syndicate includes Ventech, Gilde Healthcare Partners, Entrepreneurs Fund, Quest for Growth and Solon Ventures.

The Oxford-based Prosonix announced it will use the proceeds of the financing to push forward its product pipeline of inhalable mono- and combination therapies. “These new funds will enable Prosonix to accelerate its activities aimed at attaining key performance and clinical data for our pipeline of excipient-free, drug-only respiratory medicines”, said David Hipkiss, Prosonix' CEO. His company works on development programs for an inhaled corticosteroid for asthma and a long-acting muscarinic antagonist for chronic obstructive pulmonary disorder. Its unique Multi-component Particle (MCP™) platform enables Prosonix to combine two or more drug molecules consistently in a pre-determined ratio in each and every particle in the formulation.

Karl Nägler, Venture Capital Partner at new investor Gimv, will join the Prosonix board as a Non-executive Director. „We are confident that Prosonix can become a significant player in the area of respiratory medicines“ said Nägler, stressing that Prosonix is at an important point in its development.

http://www.european-biotechnology-news.com/news/news/2012-02/prosonix-cashes-in-pound171m.html

Clinical TrialsEUFrancePortugal

31.05.2016 The European Medicines Agency (EMA) means to increase first-in-man trial safety. Following the death of a volunteer in a Phase I trial earlier this year, the European Medicines Agency has started a review of the guidelines for first-in-man studies.

AwardFinlandEU

27.05.2016 The Finnish Technology Academy has awarded US-American innovator Frances Arnold the 2016 Millennium Technology Prize, worth €1m. Arnold is a pioneer in the field of directed evolution.

OncologyUK

26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.

MicrobiomeFranceDenmarkEU

24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.

AntibioticsEUUKItaly

20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.

LicensingGermanyIrelandSwitzerland

18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.

M&AGermany

17.05.2016 Newly rebranded Siemens Healthcare has entered the field of molecular testing for cancers with the acquisition of Cologne-based NEO New Oncology.

FinancingUK

11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.

FinancingSwitzerland

09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.

FinancingSpain

04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Basel (CH)

Chemspec Europe 2016

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTIE THERAPEUTICS (FI)0.27 EUR92.86%
  • PLETHORA (UK)3.38 GBP12.67%
  • NORDIC NANOVECTOR (N)27.10 NOK10.61%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.33%
  • 4SC (D)2.38 EUR-8.11%
  • RENEURON (UK)3.38 GBP-3.43%

TOP

  • GALAPAGOS (B)51.60 EUR30.0%
  • NICOX (F)10.95 EUR28.1%
  • GENMAB (DK)1194.00 DKK24.0%

FLOP

  • THERAMETRICS (CH)0.02 CHF-33.3%
  • 4SC (D)2.38 EUR-27.9%
  • MOBERG PHARMA (S)38.70 SEK-20.4%

TOP

  • KARO BIO (S)30.30 SEK1961.2%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • NICOX (F)10.95 EUR488.7%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)5.25 SEK-89.0%
  • BB BIOTECH (D)44.70 EUR-84.3%
  • BIOTEST (D)17.05 EUR-78.3%

No liability assumed, Date: 30.05.2016